Emergent BioSolutions (EBS) Misses Q2 EPS, Revenue
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $4.50 -1.96%
Financial Fact:
Provision for (benefit from) income taxes: 13.17M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Provision for (benefit from) income taxes: 13.17M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($0.86), $1.24 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $242.7 million versus the consensus estimate of $270.94 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla to launch Cybercab in Austin this month - report
- Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
- Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
